Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,307 | 0,317 | 13.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
SENSORION Aktie jetzt für 0€ handeln | |||||
01.07. | Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial | 239 | Business Wire | SENS-501, including the surgical delivery of the gene therapy, shows a good safety profile in all patients treated so far Three-month results from a SENS-501 treated toddler in the first... ► Artikel lesen | |
13.05. | Sensorion Publishes Results of Combined Shareholders' General Meeting Resolutions | 316 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
06.05. | Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting | 286 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
25.04. | Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting | 486 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
18.04. | Sensorion Provides Preliminary Documents for the Combined Shareholders' General Meeting of May 12, 2025 | 439 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
16.04. | Sensorion to Host a Symposium during ISIET's International Conference on Inner Ear Therapies on April 26, 2025 | 342 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
02.04. | Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director | 338 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
31.03. | Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025 | 276 | Business Wire | Sensorion to host a webconference dedicated to its retail shareholders on April 7, 2025, in French, at 6.30pm CET (12.30pm ET)
Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering... ► Artikel lesen | |
26.03. | Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences | 549 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
14.03. | Sensorion reports FY results | 4 | Seeking Alpha | ||
14.03. | Sensorion Reports Full-Year 2024 Results, Provides Corporate Update and Announces Availability of Full-Year Report | 13.005 | Business Wire | Enrolled first cohort into SENS-501's Phase 1/2 clinical trial, Audiogene, and received a positive DMC recommendation; enrollment of second cohort and KOL event to present new data expected during... ► Artikel lesen | |
07.03. | Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity | 411 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
21.02. | Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501's Audiogene Phase 1/2 Clinical Trial | 353 | Business Wire | Committee recommends continuation of Audiogene after reviewing first cohort safety data Completion of Audiogene's second cohort enrollment on track for H1 2025
Regulatory News:
Sensorion... ► Artikel lesen | |
20.02. | Sensorion Announces Its Participation in Several Investor Conferences to be Held in March | 384 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
18.02. | Sensorion Announces Its Participation In Several Congresses To Be Held In March | 378 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing... ► Artikel lesen | |
12.02. | Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 48th Annual Midwinter Meeting | 294 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders... ► Artikel lesen | |
27.12.24 | Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial | 576 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen | |
18.12.24 | Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial | 503 | Business Wire | SENS-501 gene therapy product and surgical procedure are well tolerated by the first two treated patients and encouraging behavioural changes are observed in both toddlers Sensorion plans... ► Artikel lesen | |
03.12.24 | Sensorion to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 406 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen | |
06.11.24 | Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024 | 372 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,30 | -0,67 % | BioNTech-Konkurrent Moderna: Aktie mit Kurssprung - was ist da los? | Die Aktie von Moderna hat am Dienstag einen kräftigen Kurssprung hinlegen können. Das Papier ging als Top-Gewinner des Tages im S&P 500 vor Intel und Albemarle aus dem Handel. Moderna notiert nun so... ► Artikel lesen | |
EVOTEC | 7,046 | -2,14 % | Biotech Report: Qiagen geben ab, Evotec behauptet | (shareribs.com) Frankfurt / New York 07.07.2025 - Biotech-Aktie bewegten sich im deutschen Handel überwiegend nach unten. Qiagen verloren. An der Wall Street kommt es zu Kursverlusten. Auch der Biotech-Sektor... ► Artikel lesen | |
MEDIGENE | 0,130 | -2,26 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
CUREVAC | 4,688 | +0,39 % | CureVac Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
MODERNA | 28,560 | -1,99 % | Notable healthcare headlines for the week: Trump's tariff threat, Merck, UnitedHealth and Moderna in focus | ||
VALNEVA | 2,620 | +0,92 % | Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ in Elderly | Saint Herblain (France), July, 11 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary... ► Artikel lesen | |
AMGEN | 252,35 | -0,14 % | Amgen: Vom Biotech-Innovator zur Pharma-Größe | Im Laufe der Jahre hat sich Amgen von einem klassischen Biotechnologieunternehmen mit hohem Innovationsrisiko zu einem gereiften, cashflow-starken Unternehmen entwickelt. Die Geschäftsstruktur ähnelt... ► Artikel lesen | |
EPIGENOMICS | 0,850 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Halbjahresergebnis... ► Artikel lesen | |
NOVAVAX | 5,850 | -0,10 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
BIOFRONTERA | 2,510 | 0,00 % | PTA-Adhoc: Biofrontera AG: Biofrontera Inc. Erfüllt die Bedingungen für die Umsetzung des Term Sheets mit der Biofrontera AG | DJ PTA-Adhoc: Biofrontera AG: Biofrontera Inc. Erfüllt die Bedingungen für die Umsetzung des Term Sheets mit der Biofrontera AG
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR... ► Artikel lesen | |
BIOGEN | 114,35 | -0,44 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress | - Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 -
- These findings support... ► Artikel lesen | |
HEIDELBERG PHARMA | 4,860 | +1,89 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma berichtet über das erste Halbjahr 2025 und positiven Geschäftsverlauf | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Halbjahresbericht
Heidelberg Pharma berichtet über das erste Halbjahr 2025 und positiven Geschäftsverlauf
10.07.2025 / 07:03... ► Artikel lesen | |
4SC | 1,305 | -3,69 % | PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten | DJ PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: Resminostat (Kinselby) negative Empfehlung... ► Artikel lesen | |
NANOREPRO | 1,580 | +4,98 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
CRISPR THERAPEUTICS | 48,200 | -0,82 % | Cathie Wood's ARK buys CRSP stock, sells ROKU and MASS |